We have recommended the first under-the-tongue tablet immunotherapy shown to build long-term tolerance to allergens, which could help up to 27,000 people in England with moderate to severe birch tree ...

Around 5,700 people with early breast cancer are set to benefit from expanded access to a treatment combination designed to help prevent their cancer from returning, following our recommendation, ...

Licensed for use in the UK in March, Alyftrek will now be immediately funded by the NHS in England. This rapid timeline demonstrates NICE's commitment to getting breakthrough treatments to patients ...

Around the world, publicly-funded healthcare systems face a common challenge: ensuring limited resources are allocated to treatments offering the best value for patients and taxpayers. Without robust ...

We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing ...

The technologies, which have been conditionally recommended in draft guidance, can help detect vertebral fragility fractures (VFFs) on medical images taken for unrelated condition. This means they ...

Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...

Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care Clinical guideline CG73 Published: 24 September 2008 ...

A quick guide for care home managers More than half of older adults who live in care homes have tooth decay, compared to 40% of over 75s who do not live in care homes. Poor oral health can affect ...

May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COPD see our guideline on diagnosing ...

This guideline sets out an antimicrobial prescribing strategy for adults, young people and children aged 72 hours and over with impetigo. It aims to optimise antibiotic use and reduce antibiotic ...

Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults. Commercial arrangement There is a ...